TransMedics Group, Inc. - Common Stock (TMDX)

The company is an expert in getting donated livers, hearts and lungs to transplant recipients.

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.